(0.34%) 5 117.33 points
(0.32%) 38 361 points
(0.38%) 15 989 points
(-0.85%) $83.14
(5.98%) $2.04
(0.40%) $2 356.70
(0.48%) $27.67
(3.93%) $958.30
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders...
Stats | |
---|---|
本日の出来高 | 24 811.00 |
平均出来高 | 64 143.00 |
時価総額 | 25.68M |
EPS | $0 ( 2024-03-08 ) |
次の収益日 | ( $-0.680 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.540 |
ATR14 | $0.0400 (0.83%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Patel Mahesh V. | Buy | 4 893 | Common Stock |
2024-03-08 | Fogarty Krista | Buy | 991 | Common Stock |
2023-05-25 | Patel Mahesh V. | Buy | 8 706 | Common Stock |
2023-05-10 | Papapetropoulos Spyros | Buy | 30 000 | Stock Option (Right to Buy) |
2023-05-10 | Higuchi John W. | Buy | 30 000 | Common Stock (Right to Buy) |
INSIDER POWER |
---|
93.74 |
Last 96 transactions |
Buy: 4 769 643 | Sell: 1 163 369 |
ボリューム 相関
Lipocine Inc 相関
10 最も負の相関 | |
---|---|
TYHT | -0.92 |
CNCE | -0.913 |
EPZM | -0.897 |
VERX | -0.886 |
XOG | -0.883 |
HSTM | -0.875 |
CNST | -0.866 |
BLCT | -0.859 |
AAON | -0.856 |
PLPC | -0.853 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Lipocine Inc 相関 - 通貨/商品
Lipocine Inc 財務諸表
Annual | 2023 |
収益: | $109 987 |
総利益: | $81 326.00 (73.94 %) |
EPS: | $-3.10 |
FY | 2023 |
収益: | $109 987 |
総利益: | $81 326.00 (73.94 %) |
EPS: | $-3.10 |
FY | 2022 |
収益: | $500 000 |
総利益: | $-8.06M (-1 611.38 %) |
EPS: | $-2.07 |
FY | 2021 |
収益: | $16 141.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.0000073 |
Financial Reports:
No articles found.
Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。